BR112023017200A2 - Composições orais e uso das mesmas na vacinação - Google Patents

Composições orais e uso das mesmas na vacinação

Info

Publication number
BR112023017200A2
BR112023017200A2 BR112023017200A BR112023017200A BR112023017200A2 BR 112023017200 A2 BR112023017200 A2 BR 112023017200A2 BR 112023017200 A BR112023017200 A BR 112023017200A BR 112023017200 A BR112023017200 A BR 112023017200A BR 112023017200 A2 BR112023017200 A2 BR 112023017200A2
Authority
BR
Brazil
Prior art keywords
vaccination
oral compositions
pathogen
ltb
immunizing
Prior art date
Application number
BR112023017200A
Other languages
English (en)
Inventor
Jacob Pitcovski
Morris Laster
Sigal Kremer-Tal
Original Assignee
Migvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Migvax Ltd filed Critical Migvax Ltd
Publication of BR112023017200A2 publication Critical patent/BR112023017200A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composições orais e uso das mesmas na vacinação. a presente invenção é direcionada a um método para aumentar a eficiência de imunização de um sujeito contra um patógeno, incluindo a administração de uma quantidade terapeuticamente eficaz de uma composição farmacêutica incluindo: (a) um polipeptídeo da subunidade b da toxina termolábil (ltb) ou um análogo funcional do mesmo; e (b) um polipeptídeo imunogênico derivado do patógeno.
BR112023017200A 2021-02-25 2022-02-24 Composições orais e uso das mesmas na vacinação BR112023017200A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163153545P 2021-02-25 2021-02-25
US202163184942P 2021-05-06 2021-05-06
PCT/IL2022/050217 WO2022180635A1 (en) 2021-02-25 2022-02-24 Oral compositions and use of same in vaccination

Publications (1)

Publication Number Publication Date
BR112023017200A2 true BR112023017200A2 (pt) 2023-11-21

Family

ID=83047822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017200A BR112023017200A2 (pt) 2021-02-25 2022-02-24 Composições orais e uso das mesmas na vacinação

Country Status (5)

Country Link
US (1) US20240197864A1 (pt)
EP (1) EP4297777A1 (pt)
BR (1) BR112023017200A2 (pt)
IL (1) IL305447A (pt)
WO (1) WO2022180635A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240131139A1 (en) * 2022-10-25 2024-04-25 D4 Labs, Llc Adjuvanted subcutaneously-administered polypeptide sars-cov-2 vaccines composition and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3385286A4 (en) * 2015-11-30 2019-05-01 Idemitsu Kosan Co., Ltd. ANTIGEN VACCINE WITH INCREASED IMMUNOGENICITY
CN105622760A (zh) * 2016-01-22 2016-06-01 青岛明勤生物科技有限公司 一种禽传染性支气管炎多表位粘膜免疫疫苗及其应用
US20230190923A1 (en) * 2020-02-25 2023-06-22 Migal Galilee Research Institute Ltd. Compositions comprising ltb and pathogenic antigens, and use thereof

Also Published As

Publication number Publication date
WO2022180635A1 (en) 2022-09-01
EP4297777A1 (en) 2024-01-03
US20240197864A1 (en) 2024-06-20
IL305447A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
BR112022016054A2 (pt) Composições imunogênicas para coronavírus e usos das mesmas
AR052625A1 (es) Nueva composicion
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
BR112023017200A2 (pt) Composições orais e uso das mesmas na vacinação
WO2021216743A3 (en) Coronavirus vaccines, compositions, and methods related thereto
WO2021255690A3 (en) Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CO2023003242A2 (es) Vacuna contra el coronavirus y procedimiento para la preparación de la misma
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
AR053661A1 (es) Peptido para entregar vacunas via mucosas
BR112022017032A2 (pt) Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas.
BR112021019845A2 (pt) Composições de vírus inativado e formulações de vacina contra zika
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
WO2012073257A3 (en) Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
WO2021156404A3 (en) Treatment of hpv-related diseases
EA202190914A1 (ru) Иммуногенные композиции
BR112012014689A2 (pt) composição de vacina
PH12020550239A1 (en) Periodontitis vaccine and related compositions and methods of use
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice